Discussion on the optimal dose of oral midazolam combined with dexmedetomidine for nasal sedation during MRI in children by Modified Dixon's Up - and - Down Method

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300068611

Enrollment

Unknown

Registered

2023-02-24

Start date

2023-02-27

Completion date

Unknown

Last updated

2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric procedural sedation

Interventions

Intervention group:Dexmedetomidine(modified sequential method) + midazolam

Intervention group:Dexmedetomidine + Midazolam (Modified sequential method)

Eligibility

Sex/Gender

All

Age

No minimum to 6 Years

Inclusion criteria

Inclusion criteria: (1) Age 0-6 years old, gender unlimited; (2) children undergoing MRI and requiring sedation; (3)ASA grade I-II; (4) Informed consent signed by the family members of the children; (5) No history of severe upper respiratory tract obstruction.

Exclusion criteria

Exclusion criteria: (1) nasal mucosa injury in children; (2) severe upper respiratory tract infection; (3) History of sedative drug allergy; (4) mental or conscious disorders; (5) arrhythmia, especially chronic arrhythmia; (6) Severe obesity (body weight more than 50% of the standard body weight).

Design outcomes

Primary

Measure	Time frame
Sleep Latency;Recovery time;Sedation success rate;	—

Secondary

Measure	Time frame
Heart rate;Blood pressure;Oxygen saturation;Incidence of adverse reactions;	—

Countries

China

Contacts

Public ContactYaoqin Hu

Children's hospital,School of Medicine,Zhejiang University

huyaoqin@zju.edu.cn15167112579

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 6, 2026